Efficacy of tigecycline alone and with rifampin in foreign-body infection by methicillin-resistant Staphylococcus aureus

Journal of Infection

Volumn 63, Issue 3, 2011, Pages 229-235

  Garrigos C ^a   Murillo, O ^a   Euba, G ^a   Verdaguer, R ^a   Tubau, F ^a   Cabellos, C ^a   Cabo, J ^a   Ariza, J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Foreign body infection; MRSA; Tigecycline

Indexed keywords

RIFAMPICIN; TIGECYCLINE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; FOREIGN BODY; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; RAT; SINGLE DRUG DOSE;

ANIMALS; ANTI-BACTERIAL AGENTS; DIFFUSION CHAMBERS, CULTURE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FOREIGN BODIES; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MODELS, ANIMAL; RATS; RATS, WISTAR; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 80052259840     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2011.07.001     Document Type: Article

References (35)

1. Livermore D.M. Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 2005, 56:611-614.
2. Meagher A.K., Ambrose P.G., Grasela T.H., Ellis-Grosse E.J. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005, 41(Suppl. 5):S333-S340.
3. Stein G.E., Craig W.A. Tigecycline: a critical analysis. Clin Infect Dis 2006, 43:518-524.
4. Alou L., Gimenez M.J., Cafini F., Aguilar L., Sevillano D., González N., et al. In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline. J Antimicrob Chemother 2009, 64:1230-1233.
5. Tygacil product monograph 2009, Wyeth Pharmaceuticals Inc., Wyeth Pharmaceuticals Inc., Philadelphia, PA, [accessed 14.12.09]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s013s017s018lbl.pdf.
6. Murphy T.M., Deitz J.M., Petersen P.J., Mikels S.M., Weiss W.J. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000, 44:3022-3027.
7. Vaudaux P., Fleury B., Gjinovci A., Huggler E., Tangomo-Bento M., Lew D.P. Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:3150-3152.
8. Yin L.Y., Lazzarini L., Li F., Stevens C.M., Calhoun J.H. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005, 55:995-1002.
9. Entenza J.M., Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009, 34(8):e1-9.
10. Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
11. Chuard C., Lucet J.C., Rohner P., Herrmann M., Auckenthaler R., Waldvogel F.A., et al. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis 1991, 163:1369-1373.
12. Zimmerli W., Trampuz A., Ochsner P.E. Prosthetic-joint infections. N Engl J Med 2004, 351:1645-1654.
13. Zimmerli W., Widmer A.F., Blatter M., Frei R., Ochsner P.E. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) study group. JAMA 1998, 279:1537-1541.
14. Drancourt M., Stein A., Argenson J.N., Zannier A., Curvale G., Raoult D. Oral rifampin plus ofloxacin for treatment of staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother 1993, 37:1214-1218.
15. Van der Auwera P., Klastersky J., Thys J.P., Meunier-Carpentier F., Legrand J.C. Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections. Antimicrob Agents Chemother 1985, 28:467-472.
16. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52:285-292.
17. Lucet J.C., Herrmann M., Rohner P., Auckenthaler R., Waldvogel F.A., Lew D.P. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990, 34:2312-2317.
18. Zimmerli W., Waldvogel F.A., Vaudaux P., Nydegger U.E. Pathogenesis of foreign body infection: description and characteristics of an animal model. J Infect Dis 1982, 146:487-497.
19. Zimmerli W., Frei R., Widmer A.F., Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother 1994, 33:959-967.
20. Murillo O., Domenech A., Garcia A., Tubau F., Cabellos C., Gudiol F., et al. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50:4011-4017.
21. Murillo O., Garrigos C., Pachon M.E., Euba G., Verdaguer R., Cabellos C., et al. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53:4252-4257.
22. Murillo O., Domenech A., Euba G., Verdaguer R., Tubau F., Cabo J., et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infect 2008, 57:229-235.
23. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically 2009, Clinical and Laboratory Standards Institute, Approved Standard, CLSI, Wayne, PA, USA, M07-A8. 8th ed.
24. Methods for determining bactericidal activity of antimicrobial agents. M26-A 1999, National Committee for Clinical Laboratory Standards, National Committee for Clinical Laboratory Standards, Villanova, PA.
25. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:11-12. 1-10; quiz.
26. Trampuz A., Wenk M., Rajacic Z., Zimmerli W. Pharmacokinetics and pharmacodynamics of levofloxacin against Streptococcus pneumoniae and Staphylococcus aureus in human skin blister fluid. Antimicrob Agents Chemother 2000, 44:1352-1355.
27. Chapin-Robertson K., Edberg S.C. Measurements of antibiotics in human body fluids: techniques and significance. Antibiotics in laboratory medicine 1991, 295-366. The Williams & Wilkins Co., New York, NY. V. Lorian (Ed.).
28. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1 April 2010, European Committee on Antimicrobial Susceptibility Testing (EUCAST), [accessed 10.06.10]. http://www.eucast.org/clinical_breakpoints/.
29. Mercier R.C., Kennedy C., Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002, 22:1517-1523.
30. Vouillamoz J., Moreillon P., Giddey M., Entenza J.M. In vitro activities of tigecycline combined with other antimicrobials against multiresistant gram-positive and gram-negative pathogens. J Antimicrob Chemother 2008, 61:371-374.
31. Kollef M.H. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis 2007, 45(Suppl. 3):S191-S195.
32. Soriano A., Marco F., Martinez J.A., Pisos E., Almela M., Dimova V.P., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46:193-200.
33. Meagher A.K., Ambrose P.G., Grasela T.H., Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005, 52:165-171.
34. Ambrose P.G., Meagher A.K., Passarell J.A., Van Wart S.A., Cirincione B.B., Bhavnani S.M., et al. Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci. Diagn Microbiol Infect Dis 2009, 63:155-159.
35. Raad I., Hanna H., Jiang Y., Dvorak T., Reitzel R., Chaiban G., et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007, 51:1656-1660.